Complete Response to R-EPOCH in Primary Cardiac Lymphoma

  • Anand K
  • Pingali S
  • Trachtenberg B
  • et al.
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Primary cardiac lymphoma (PCL) is a rare extranodal lymphoma involving only the heart and/or the pericardium. Most common presenting signs and symptoms are nonspecific including dyspnea, pericardial effusion, and arrhythmia. Prognosis of PCL patients remain poor compared to non‐cardiac lymphoma patients. Since most of the information about PCL comes from case reports or case series, there is no treatment consensus. Anthracycline containing chemotherapy remains main treatment modality which is potentially cardiotoxic. We present a case of PCL that achieved complete remission using R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin). We also used dexrazoxane in an effort to reduce cardiotoxicity of chemotherapy.

Cite

CITATION STYLE

APA

Anand, K., Pingali, S. R., Trachtenberg, B., & Iyer, S. P. (2019). Complete Response to R-EPOCH in Primary Cardiac Lymphoma. Case Reports in Hematology, 2019, 1–4. https://doi.org/10.1155/2019/7690430

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free